Lipoprotein metabolism & CV risk: a long road from understanding to treatment
Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.
Video navigation menu
- New insights into the LDL-c axis 00:42
- Residual risk after eradication of LDL-c 02:12
- Novel therapies to address remnant cholesterol 03:29
- The Lp(a) axis 04:48
- The long way from understanding of lipoprotein metabolism to treatment 06:08
There are 3 major disturbances in lipoprotein metabolism that confer a CV risk. After LDL-c eradication, a residual risk remains that can be addressed by novel therapies that are currently being developed. This recording aims to summarize these developments and their practical implications.
Prof. John J.P. Kastelein is Professor of Medicine atthe Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this recording.
Share this page with your colleagues and friends: